FindTrial
Sign In

An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptoms

Status
Withdrawn
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523699-21-00
Enrollment
40
Registered
2026-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum disorder, Gastrointestinal symptoms

Brief summary

Number of adverse reactions (ARs) and serious adverse reactions (SARs)

Detailed description

Change in Vineland Adaptive Behavior Scales (questionnaire), Change in Children Communication Checklist-2 (questionnaire), Change in IBS-QoL - Irritable Bowel Syndrome Quality of Life (questionnaire)

Interventions

DRUGC2C_ASC110
DRUGC2C_ASC66

Sponsors

Cell to Cure ApS
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Number of adverse reactions (ARs) and serious adverse reactions (SARs)—

Secondary

MeasureTime frame
Change in Vineland Adaptive Behavior Scales (questionnaire), Change in Children Communication Checklist-2 (questionnaire), Change in IBS-QoL - Irritable Bowel Syndrome Quality of Life (questionnaire)—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026